Fatema Nagib
Research Subjects
Fatema Nagib has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Danny N. Khalil
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
7 shared publications - Darren Cowzer
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications - David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
7 shared publications - Eileen Mary O'Reilly
Weill Cornell Medicine
7 shared publications - Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center, New York, New York, USA
7 shared publications - James J. Harding
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
7 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Target Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.
- 14 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Open AccessTarget Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 1: Consort diagram depicting patient/sample exclusions. Untreated groups are at an alteration level, where patients harboring the specific alteration are included in the groups; patients can be in more than one untreated group. Treatment groups are determined by the matched therapy that the patient received.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 1: Consort diagram depicting patient/sample exclusions. Untreated groups are at an alteration level, where patients harboring the specific alteration are included in the groups; patients can be in more than one untreated group. Treatment groups are determined by the matched therapy that the patient received.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 2: A. Comparison of gene-level alterations showing significant differences across BTC subtypes. B. Comparison of oncogenic signaling pathway alterations across BTC subtypes. C. Comparison of gene-level alteration between different age groups divided into decades. D. Percentage of samples with clonal, subclonal, and indeterminate mutations broken down by subtype. Proportion of clonal, subclonal, and indeterminate mutations broken down by subtypes. E. Oncoprint comparing the tumors with subclonal ERBB2 mutations to those with clonal mutations. F. Comparison of actionability in 2017 and 2023 across subtypes. G. Percentage of patients getting targeted therapy over the years, with drug approvals plotted below. Fifteen patients who received HAI treatment only, as well as 1 patient treated outside of MSK, were excluded from the plot.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 2: A. Comparison of gene-level alterations showing significant differences across BTC subtypes. B. Comparison of oncogenic signaling pathway alterations across BTC subtypes. C. Comparison of gene-level alteration between different age groups divided into decades. D. Percentage of samples with clonal, subclonal, and indeterminate mutations broken down by subtype. Proportion of clonal, subclonal, and indeterminate mutations broken down by subtypes. E. Oncoprint comparing the tumors with subclonal ERBB2 mutations to those with clonal mutations. F. Comparison of actionability in 2017 and 2023 across subtypes. G. Percentage of patients getting targeted therapy over the years, with drug approvals plotted below. Fifteen patients who received HAI treatment only, as well as 1 patient treated outside of MSK, were excluded from the plot.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 3: A. Swimmers plot showing progressing free survival from the start of second-line therapy comparing patients who received 5-fu based treatment versus targeted therapy. B. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients, excluding those treated with immunotherapy. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. C. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients with an OncoKB level 1 or level 2 alteration. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. D. Swimmers plot showing the progression-free survival in BRAFi-treated patients. Kaplan–Meier overall survival curves comparing patients harboring BRAF class I mutation with a targeted therapy to those who did not. E. Swimmers plots of overall survival comparing treated and untreated targeted therapy cohorts (IDH1/2 mutated, FGFR2i-treated, and ERBB2i-treated patients). F. Kaplan–Meier overall curves comparing overall survival from the start of second-line therapy between treated and untreated samples in the entire immunotherapy cohort, then stratified into MSI patients and TMB-high patient subgroups. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. G. Swimmer’s plot depicting the progression-free survival in patients treated with immunotherapy, with an oncoprint depicting genes commonly altered in MSI tumors and a proportionality plot for the types of mutations within each tumor and sample-level TMB and MSI annotations.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 3: A. Swimmers plot showing progressing free survival from the start of second-line therapy comparing patients who received 5-fu based treatment versus targeted therapy. B. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients, excluding those treated with immunotherapy. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. C. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients with an OncoKB level 1 or level 2 alteration. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. D. Swimmers plot showing the progression-free survival in BRAFi-treated patients. Kaplan–Meier overall survival curves comparing patients harboring BRAF class I mutation with a targeted therapy to those who did not. E. Swimmers plots of overall survival comparing treated and untreated targeted therapy cohorts (IDH1/2 mutated, FGFR2i-treated, and ERBB2i-treated patients). F. Kaplan–Meier overall curves comparing overall survival from the start of second-line therapy between treated and untreated samples in the entire immunotherapy cohort, then stratified into MSI patients and TMB-high patient subgroups. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. G. Swimmer’s plot depicting the progression-free survival in patients treated with immunotherapy, with an oncoprint depicting genes commonly altered in MSI tumors and a proportionality plot for the types of mutations within each tumor and sample-level TMB and MSI annotations.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 4: A. Bar plot showing shared and unshared mutations between pre- and post-treatment samples. B. Oncoprint comparing pre- and post-treatment samples in ERBB2, FGFR2, and BRAF treatment cohorts. C. Lollipop plots for specific mutations in KRAS and MAP2K1 detected in the sequential samples from the BRAF targeted therapy-treated patient.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 4: A. Bar plot showing shared and unshared mutations between pre- and post-treatment samples. B. Oncoprint comparing pre- and post-treatment samples in ERBB2, FGFR2, and BRAF treatment cohorts. C. Lollipop plots for specific mutations in KRAS and MAP2K1 detected in the sequential samples from the BRAF targeted therapy-treated patient.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Table S1. Cohort demographics Table S2: Clinically eligible for matched-targeted therapy cohort demographics of molecularly defined Subgroups Table S3: Genes included on MSK-IMPACT Panels Table S4: Comparison of gene-level alteration frequency by BTC Subtypes Table S5: Comparison of pathway-level alteration frequency by BTC Subtypes Table S6: Actionable alterations in patients without targeted therapy due to unavailability Table S7: Comparison of clinical characteristics between treatment groups Table S8: Comparison of gene-level alterations between treatment groups Table S9: Summary of OS univariate analysis (Full cohort) Table S10: Overall Survival analysis of Molecularly Defined Subgroups
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Table S1. Cohort demographics Table S2: Clinically eligible for matched-targeted therapy cohort demographics of molecularly defined Subgroups Table S3: Genes included on MSK-IMPACT Panels Table S4: Comparison of gene-level alteration frequency by BTC Subtypes Table S5: Comparison of pathway-level alteration frequency by BTC Subtypes Table S6: Actionable alterations in patients without targeted therapy due to unavailability Table S7: Comparison of clinical characteristics between treatment groups Table S8: Comparison of gene-level alterations between treatment groups Table S9: Summary of OS univariate analysis (Full cohort) Table S10: Overall Survival analysis of Molecularly Defined Subgroups
- 26 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4166-4177
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Purpose: Actionable genomic alterations occur in all anatomic subsets of biliary tract cancer (BTC); however, targeted therapies have not shown a survival advantage over cytotoxics, and resistance mechanisms require further characterization. Experimental Design: We analyzed a prospectively maintained cohort of 1254 patients with histologically confirmed BTC who underwent molecular profiling using an FDA-authorized targeted next-generation sequencing assay. We defined actionable alterations across anatomic subsets, compared outcomes with targeted therapy versus cytotoxics, and evaluated genomic correlates of resistance using longitudinal samples. Results: Overall, 59% of patients harbored at least one OncoKB alteration, and 32.2% (intrahepatic 40%, extrahepatic 15%, gallbladder 22%) had a level 1/2 alteration. Emerging targets included KRAS alterations (17%), MTAP deletions (12.8%), MDM2 amplification (6.5%), and MET amplification (1.5%). Targeted therapy was associated with improved progression-free survival but not overall survival. Co-occurring TP53/RAS pathway and SMAD4 alterations were associated with inferior outcomes in IDH1/FGFR2- and ERBB2-driven tumors, respectively. Longitudinal profiling demonstrated ERBB2 loss in ERBB2-driven tumors, whereas IDH-, FGFR-, BRAF-, and NTRK-driven tumors retained the primary oncogenic driver. Acquired resistance was associated with alterations in RAS, MEK, MET, MYC, and CDKN2A. Conclusions: This comprehensive molecular profiling study illustrates the real-world utility and limitations of targeted next-generation sequencing of BTC and affirms the use of precision medicine in patients with these diseases. Characterization of genomic heterogeneity and therapeutic resistance has the potential to inform ongoing drug development efforts for BTC.
- 26 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4166-4177
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Purpose: Actionable genomic alterations occur in all anatomic subsets of biliary tract cancer (BTC); however, targeted therapies have not shown a survival advantage over cytotoxics, and resistance mechanisms require further characterization. Experimental Design: We analyzed a prospectively maintained cohort of 1254 patients with histologically confirmed BTC who underwent molecular profiling using an FDA-authorized targeted next-generation sequencing assay. We defined actionable alterations across anatomic subsets, compared outcomes with targeted therapy versus cytotoxics, and evaluated genomic correlates of resistance using longitudinal samples. Results: Overall, 59% of patients harbored at least one OncoKB alteration, and 32.2% (intrahepatic 40%, extrahepatic 15%, gallbladder 22%) had a level 1/2 alteration. Emerging targets included KRAS alterations (17%), MTAP deletions (12.8%), MDM2 amplification (6.5%), and MET amplification (1.5%). Targeted therapy was associated with improved progression-free survival but not overall survival. Co-occurring TP53/RAS pathway and SMAD4 alterations were associated with inferior outcomes in IDH1/FGFR2- and ERBB2-driven tumors, respectively. Longitudinal profiling demonstrated ERBB2 loss in ERBB2-driven tumors, whereas IDH-, FGFR-, BRAF-, and NTRK-driven tumors retained the primary oncogenic driver. Acquired resistance was associated with alterations in RAS, MEK, MET, MYC, and CDKN2A. Conclusions: This comprehensive molecular profiling study illustrates the real-world utility and limitations of targeted next-generation sequencing of BTC and affirms the use of precision medicine in patients with these diseases. Characterization of genomic heterogeneity and therapeutic resistance has the potential to inform ongoing drug development efforts for BTC.